Simple Blood Test Calculation Predicts Survival in Brain Tumor Patients

A simple blood test calculation could soon help doctors predict the outlook for patients fighting brain tumors. Researchers have found that a measure called the systemic inflammation response index, which combines three common types of white blood cells, is linked to survival times in people diagnosed with gliomas.

Gliomas are the most common type of primary malignant brain tumor in adults, with aggressive forms like glioblastoma presenting immense challenges for patients and doctors alike. These tumors typically have a five-year survival rate of less than 10 percent. Traditional prognostic assessments rely heavily on age, tumor grade, and specific genetic markers, but these indicators do not always capture how a patient’s entire body is reacting to the disease in real time. Inflammation plays a central role in tumor growth and progression, prompting researchers to look at easily accessible blood markers to bridge this gap in risk stratification.

To evaluate whether this inflammation measure could reliably forecast patient trajectories, the research team conducted a comprehensive review and meta-analysis of existing literature. The study is published in PLOS One. The systemic inflammation response index, abbreviated as SIRI, is calculated by multiplying the neutrophil count by the monocyte count and then dividing the result by the lymphocyte count. Neutrophils and monocytes often promote inflammation and help tumors grow, whereas lymphocytes act as part of the body’s natural defense mechanism to fight cancer.

What the Pooled Data Revealed About Survival Times

The investigators searched major medical databases for relevant studies published up to July 2026. Their final analysis incorporated eight retrospective cohort studies encompassing 1,778 patients, yielding ten comparison groups for overall survival and four comparison groups for progression-free survival.

The pooled statistical evaluation demonstrated that elevated baseline SIRI values were significantly associated with a shortened overall survival, yielding a hazard ratio of 1.79. This means patients with higher inflammation index scores faced a notably higher risk of mortality during the follow-up periods. Similarly, analysis of progression-free survival across 607 patients showed that higher SIRI levels were linked to shorter periods before the disease advanced, with a hazard ratio of 1.46.

Why Brain Tumors Trigger Systemic Immune Shifts

The connection between blood cell counts and brain tumor severity lies within the tumor microenvironment. High-grade gliomas and glioblastomas are notoriously invasive and create a heavily immunosuppressed environment that fuels rapid cellular proliferation. As the body mounts an immune response against the expanding mass, systemic inflammation spikes, altering the balance of circulating white blood cells.

While other hematological markers such as the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio have been studied in oncology, SIRI provides a broader view by integrating three distinct immune cell lineages. Neutrophils contribute to tissue remodeling and angiogenesis, which is the formation of new blood vessels that feed the tumor. Monocytes can differentiate into tumor-associated macrophages that further support cancer growth, while lymphocytes are suppressed, weakening the body’s anti-tumor immunity.

Limitations and Questions for Future Research

Despite the consistent overall findings, the authors emphasized several important limitations. All the included studies were retrospective, meaning they looked backward at existing patient records rather than following patients forward in real time. Furthermore, the studies used varying numerical cutoff points to divide patients into high and low SIRI groups, ranging from 1.26 to 2.55, which introduces statistical variability.

Geographic bias was also present, as the vast majority of the study populations were from Asian cohorts, leaving the predictive value in European and other populations less certain. Unmeasured factors such as the use of corticosteroids during the perioperative period could also influence white blood cell counts independently of the tumor. Future prospective research with standardized cutoffs and diverse patient groups will be necessary before this blood index can be routinely integrated into clinical decision-making.

The research was published in PLOS One on November 2, 2026.